Compare · ABBV vs AMRN
ABBV vs AMRN
Side-by-side comparison of AbbVie Inc. (ABBV) and Amarin Corporation plc (AMRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and AMRN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $440.83B, about 1483.3x AMRN ($297.2M).
- Over the past year, ABBV is up 20.6% and AMRN is down 9.3% - ABBV leads by 29.9 points.
- ABBV has been more active in the news (17 items in the past 4 weeks vs 4 for AMRN).
- ABBV has more recent analyst coverage (25 ratings vs 10 for AMRN).
- Company
- AbbVie Inc.
- Amarin Corporation plc
- Price
- $249.34-0.56%
- $14.04-0.92%
- Market cap
- $440.83B
- $297.2M
- 1M return
- -1.98%
- -0.88%
- 1Y return
- +20.62%
- -9.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 17
- 4
- Recent ratings
- 25
- 10
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Latest ABBV
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- AbbVie upgraded by Erste Group
- SEC Form FWP filed by AbbVie Inc.
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- SEC Form 424B5 filed by AbbVie Inc.
- Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
Latest AMRN
- SVP, CFO Fishman Peter L. converted options into 313 units of American Depositary Share and covered exercise/tax liability with 155 units of American Depositary Share, increasing direct ownership by 2% to 7,619 units (SEC Form 4)
- SEC Form 10-Q filed by Amarin Corporation plc
- Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition
- Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
- EVP, Chief Scientific Officer Ketchum Steven B converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,887 units of American Depositary Shares, increasing direct ownership by 4% to 42,680 units (SEC Form 4)
- EVP, Chief Operating Officer Keenan David Paul converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,926 units of American Depositary Shares, increasing direct ownership by 15% to 13,470 units (SEC Form 4)
- SVP, CFO Fishman Peter L. converted options into 2,447 units of American Depositary Shares and covered exercise/tax liability with 1,206 units of American Depositary Shares, increasing direct ownership by 20% to 7,461 units (SEC Form 4)
- EVP, Chief Legal Officer Provoost Jonathan converted options into 3,688 units of American Depositary Shares and covered exercise/tax liability with 1,264 units of American Depositary Shares, increasing direct ownership by 110% to 4,624 units (SEC Form 4)
- Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
- President and CEO Berg Aaron converted options into 6,250 units of American Depositary Shares and covered exercise/tax liability with 3,197 units of American Depositary Shares, increasing direct ownership by 4% to 85,648 units (SEC Form 4)